Patents by Inventor Masahiro Neya

Masahiro Neya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11891412
    Abstract: The purpose of the present invention is to provide a method for purifying and preparing a highly liposoluble phosphoramidite, as well as a capping reaction using the highly liposoluble phosphoramidite compound, and as well as a method for preparing oligonucleotide by a liquid phase process using a pseudo solid phase protecting group said method comprising the capping reaction step.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: February 6, 2024
    Assignee: KNC LABORATORIES CO., LTD.
    Inventors: Tsuyoshi Fujihara, Kenichi Nakamura, Toru Kurome, Daisuke Sasahara, Akiko Shimahara, Masahiro Neya
  • Publication number: 20230272403
    Abstract: An antisense oligonucleotide is provided which induces exon skipping in ACE2 gene. An antisense oligonucleotide of 15-30 bases or a salt or a solvate thereof, wherein the antisense oligonucleotide has a nucleotide sequence complementary to a target site in exon 18 of angiotensin-converting enzyme 2 gene and is capable of inducing exon skipping in angiotensin-converting enzyme 2 gene. A pharmaceutical drug comprising the antisense oligonucleotide or a salt or a solvate thereof; and an agent for inhibiting the expression of angiotensin-converting enzyme 2 protein and/or for enhancing the expression of soluble angiotensin-converting enzyme 2.
    Type: Application
    Filed: July 19, 2021
    Publication date: August 31, 2023
    Applicants: KNC LABORATORIES CO., LTD., KOBE GAKUIN EDUCATIONAL FOUNDATION
    Inventors: Masafumi MATSUO, Kazuhiro MAETA, Tsuyoshi FUJIHARA, Itaru OKAMOTO, Masahiro NEYA
  • Publication number: 20210230598
    Abstract: The present invention provides a tau exon 10 skipping-promoting antisense oligonucleotide containing at least one 2?-O, 4?-C-ethylene-bridged nucleic acid, and a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a region consisting of the nucleotide sequence shown in SEQ ID NO: 44 in exon 10 of a tau mRNA precursor. In addition, the present invention provides a tau exon 10 skipping-suppressing antisense oligonucleotide containing at least one 2?-O, 4?-C-ethylene-bridged nucleic acid, and a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a region consisting of the nucleotide sequence shown in SEQ ID NO: 45 in intron 10 of a tau mRNA precursor.
    Type: Application
    Filed: July 3, 2019
    Publication date: July 29, 2021
    Applicants: NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM, KNC LABORATORIES CO., LTD.
    Inventors: Gen SOBUE, Kentaro SAHASHI, Shinsuke ISHIGAKI, Kuniyuki ENDO, Tsuyoshi FUJIHARA, Masahiro NEYA, Seiji MATSUDA
  • Patent number: 11028390
    Abstract: The present invention provides a suppression type antisense oligonucleotide targeting TDP-43 mRNA, containing a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a nucleotide sequence shown in any of SEQ ID NOs: 2-4, and a promotion type antisense oligonucleotide targeting TDP-43 mRNA, containing a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a nucleotide sequence shown in SEQ ID NO: 5.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: June 8, 2021
    Assignees: Osaka University, KNC Laboratories Co., Ltd., Aichi Medical University
    Inventors: Yoshitaka Nagai, Kazuhiro Maeta, Toshihide Takeuchi, Masahiro Neya, Tsuyoshi Fujihara, Seiji Matsuda, Gen Sobue, Shinsuke Ishigaki, Kentaro Sahashi
  • Publication number: 20210087220
    Abstract: The purpose of the present invention is to provide a method for purifying and preparing a highly liposoluble phosphoramidite, as well as a capping reaction using the highly liposoluble phosphoramidite compound, and as well as a method for preparing oligonucleotide by a liquid phase process using a pseudo solid phase protecting group said method comprising the capping reaction step.
    Type: Application
    Filed: December 26, 2018
    Publication date: March 25, 2021
    Inventors: Tsuyoshi FUJIHARA, Kenichi NAKAMURA, Toru KUROME, Daisuke SASAHARA, Akiko SHIMAHARA, Masahiro NEYA
  • Patent number: 10899790
    Abstract: Provided are: a compound represented by formula (I); a retinoid metabolic pathway inhibitor comprising the same; an agent for increasing the ratio of memory T cells; a prophylactic and/or therapeutic agent for cancer or an infectious disease; a cancer immunotherapeutic adjuvant; an immunopotentiator; and a method for preparing a T cell population wherein the ratio of memory T cells is increased, said method comprising using the compound of formula (I).
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: January 26, 2021
    Assignees: OSAKA UNIVERSITY, KNC LABORATORIES CO., LTD.
    Inventors: Haruo Sugiyama, Fumihiro Fujiki, Masahiro Neya, Shinya Kohno
  • Publication number: 20200165610
    Abstract: The present invention provides a suppression type antisense oligonucleotide targeting TDP-43 mRNA, containing a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a nucleotide sequence shown in any of SEQ ID NOs: 2-4, and a promotion type antisense oligonucleotide targeting TDP-43 mRNA, containing a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a nucleotide sequence shown in SEQ ID NO: 5.
    Type: Application
    Filed: July 6, 2018
    Publication date: May 28, 2020
    Applicants: OSAKA UNIVERSITY, KNC LABORATORIES CO., LTD., NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
    Inventors: Yoshitaka NAGAI, Kazuhiro MAETA, Toshihide TAKEUCHI, Masahiro NEYA, Tsuyoshi FUJIHARA, Seiji MATSUDA, Gen SOBUE, Shinsuke ISHIGAKI, Kentaro SAHASHI
  • Publication number: 20190284228
    Abstract: Provided are: a compound represented by formula (I); a retinoid metabolic pathway inhibitor comprising the same; an agent for increasing the ratio of memory T cells; a prophylactic and/or therapeutic agent for cancer or an infectious disease; a cancer immunotherapeutic adjuvant; an immunopotentiator; and a method for preparing a T cell population wherein the ratio of memory T cells is increased, said method comprising using the compound of formula (I).
    Type: Application
    Filed: November 8, 2017
    Publication date: September 19, 2019
    Applicants: OSAKA UNIVERSITY, KNC LABORATORIES CO., LTD.
    Inventors: Haruo SUGIYAMA, Fumihiro FUJIKI, Masahiro NEYA, Shinya KOHNO
  • Patent number: 9771316
    Abstract: The invention provides a compound having a selective inhibitory activity against highly-expressed LAT-1 in tumor cell. The compound is represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, and a LAT-1 inhibitor comprising the same.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: September 26, 2017
    Assignees: Osaka University, KNC Laboratories Co., Ltd.
    Inventors: Yoshikatsu Kanai, Shushi Nagamori, Yoshihiko Kitaura, Masahiro Neya, Naohiro Matsushita
  • Publication number: 20150336876
    Abstract: The invention provides a compound having a selective inhibitory activity against highly-expressed LAT-1 in tumor cell. The compound is represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, and a LAT-1 inhibitor comprising the same.
    Type: Application
    Filed: January 21, 2014
    Publication date: November 26, 2015
    Inventors: Yoshikatsu KANAI, Shushi NAGAMORI, Yoshihiko KITAURA, Masahiro NEYA, Naohiro MATSUSHITA
  • Patent number: 9056862
    Abstract: The present invention provides an anticancer drug having a Ras function inhibitory action. The present invention provides a Ras function inhibitor comprising a compound represented by the formula (I?): wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: June 16, 2015
    Assignees: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, KNC LABORATORIES CO., LTD.
    Inventors: Tohru Kataoka, Fumi Shima, Masahiro Neya, Daisuke Sasahara
  • Patent number: 8802679
    Abstract: Compounds of formula (I) defined herein exhibit VAP-1 inhibitory activity, and as a result, are useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: August 12, 2014
    Assignee: Astellas Pharma Inc.
    Inventors: Kousei Yoshihara, Daisuke Suzuki, Susumu Yamaki, Yuji Koga, Norio Seki, Jiro Fujiyasu, Masahiro Neya
  • Publication number: 20140194412
    Abstract: The present invention provides an anticancer drug having a Ras function inhibitory action. The present invention provides a Ras function inhibitor comprising a compound represented by the formula (I?): wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Application
    Filed: May 9, 2012
    Publication date: July 10, 2014
    Applicants: KNC LABORATORIES CO., LTD., NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY
    Inventors: Tohru Kataoka, Fumi Shima, Masahiro Neya, Daisuke Sasahara
  • Patent number: 8252895
    Abstract: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal.
    Type: Grant
    Filed: July 21, 2010
    Date of Patent: August 28, 2012
    Assignee: Astellas Pharma Inc.
    Inventors: Masahiro Neya, Seiji Yoshimura, Kazunori Kamijyo, Takuya Makino, Minoru Yasuda, Toshio Yamanaka, Eisaku Tsujii, Yukiko Yamagishi
  • Publication number: 20120184520
    Abstract: [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.
    Type: Application
    Filed: September 15, 2010
    Publication date: July 19, 2012
    Applicant: Astellas Pharma Inc.
    Inventors: Kousei Yoshihara, Daisuke Suzuki, Susumu Yamaki, Yuji Koga, Norio Seki, Jiro Fujiyasu, Masahiro Neya
  • Patent number: 7872097
    Abstract: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal.
    Type: Grant
    Filed: October 26, 2006
    Date of Patent: January 18, 2011
    Assignee: Astellas Pharma Inc.
    Inventors: Masahiro Neya, Seiji Yoshimura, Kazunori Kamijyo, Takuya Makino, Minoru Yasuda, Toshio Yamanaka, Eisaku Tsujii, Yukiko Yamagishi
  • Publication number: 20100286033
    Abstract: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal.
    Type: Application
    Filed: July 21, 2010
    Publication date: November 11, 2010
    Inventors: Masahiro NEYA, Seiji Yoshimura, Kazunori Kamijyo, Takuya Makino, Minoru Yasuda, Toshio Yamanaka, Eisaku Tsujii, Yukiko Yamagishi
  • Publication number: 20090170755
    Abstract: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal.
    Type: Application
    Filed: October 26, 2006
    Publication date: July 2, 2009
    Inventors: Masahiro Neya, Seiji Yoshimura, Kazunori Kamijyo, Takuya Makino, Minoru Yasuda, Toshio Yamanaka, Eisaku Tsujii, Yukiko Yamagishi
  • Patent number: 6967197
    Abstract: A compound of formula (I) in which R1 is halo, lower alkoxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterecyclic group or optionally substituted lower alkynyl, R2 is amidated carboxy, R3 is hydrogen or acyl, Ar is aryl or heterocyclic group, X is thia, sulfinyl or sulfonyl, Y and Z are each lower alkylene, m and n are each an integer of 0 to 2, and a salt thereof, useful as inhibitors of matrix metalloproteinases (MMP) or the production of tumor necrosis factor ? (TNF ?)
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: November 22, 2005
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Masahiro Neya, Hitoshi Yamazaki, Kazuhiko Ohne, Yuki Sawada, Tsuyoshi Mizutani, Yoshimasa Imamura, Noriko Mukai
  • Publication number: 20040266826
    Abstract: A compound of the formula: in which R1 is optionally substituted phenyl, optionally substituted naphthyl, optionally substituted bicyclic heterocyclic group, optionally substituted lower alkenyl or optionally substituted lower alkynyl, and R2 is carboxy or protected carboxy, or a salt thereof, useful for treating and/or preventing MMP- or TNF-&agr; mediated diseases.
    Type: Application
    Filed: February 27, 2004
    Publication date: December 30, 2004
    Inventors: Masahiro Neya, Akihiko Sawada, Kazuhiko Ohne, Yoshito Abe, Tsuyoshi Mizutani, Naoki Ishibashi, Makoto Inoue